Drug Profile
Research programme: anti-angiogenic gene therapy - Oxford BioMedica
Alternative Names: Angiostatin/endostatin cancer gene therapy - Oxford BioMedica; EndoAngio-GTLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Oxford BioMedica
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 10 Jul 2007 Preclinical trials in Cancer in United Kingdom (unspecified route)